Bioequivalence study of a new sildenafil 100 mg orodispersible film compared to the conventional film-coated 100 mg tablet administered to healthy male volunteers

The pattern of responses was similar for the other principal

Benefits of V-ORAL STRIPS 100 mg

This is consistent with ritonavir’s marked effects on a broad range of P450 substrates. Sildenafil had no effect on ritonavir pharmacokinetics [ sildenafil 50 mg tab see Dosage and Administration (2.2) and Drug Interactions (7.4)]. Although the interaction between other protease inhibitors and sildenafil has not been studied, their concomitant use is expected to increase sildenafil levels. In a study of healthy male volunteers, co-administration of sildenafil at steady state (80 mg t.i.d.) with endothelin receptor antagonist bosentan (a moderate inducer of CYP3A4, CYP2C9 and possibly of CYP2C19) at steady state (125 mg b.i.d.) resulted in a 63% decrease of sildenafil AUC and a 55% decrease in sildenafil Cmax. Concomitant administration of strong CYP3A4 inducers, such as rifampin, is expected to cause greater decreases in plasma levels of sildenafil.

12.2 Pharmacodynamics

Single doses of antacid (magnesium hydroxide/aluminum hydroxide) did not affect the bioavailability of sildenafil citrate. In healthy male volunteers, there was no evidence of a clinically significant effect of azithromycin (500 mg daily for 3 days) on the systemic exposure of sildenafil or its major circulating metabolite. Pharmacokinetic data from patients in clinical trials showed no effect on sildenafil pharmacokinetics of CYP2C9 inhibitors (such as tolbutamide, warfarin), CYP2D6 inhibitors (such as selective serotonin reuptake inhibitors, tricyclic antidepressants), thiazide and related diuretics, ACE inhibitors, and calcium channel blockers. The AUC of the active metabolite, N-desmethyl sildenafil, was increased 62% by loop and potassium-sparing diuretics and 102% by nonspecific beta-blockers. These effects on the metabolite are not expected to be of clinical consequence. question, the ability to achieve an erection sufficient for intercourse.

Product	Dosage	Quantity + Bonus	Price
Viagra Generic	150mg	20 Pills	55.02€ 52.40€	Buy
Viagra Generic	200mg	180 + 10 Pills	277.56€ 264.34€	Buy
Viagra Generic	150mg	180 + 10 Pills	236.46€ 225.20€	Buy
Kamagra Soft Tabs	100mg	32 Pills	120.11€ 114.39€	Buy
Viagra Generic	25mg	20 Pills	37.74€ 35.94€	Buy
Viagra Generic	25mg	180 + 6 Pills	154.93€ 147.55€	Buy
Viagra Generic	25mg	120 + 6 Pills	125.56€ 119.58€	Buy
Kamagra	100mg	12 Pills	55.64€ 52.99€	Buy
Kamagra Oral Jelly	100mg	10 Sachets	54.55€ 51.95€	Buy
Viagra Generic	50mg	10 Pills	26.87€ 25.59€	Buy
Viagra Generic	50mg	180 + 8 Pills	158.82€ 151.26€	Buy
Viagra Generic	150mg	360 + 10 Pills	423.48€ 403.31€	Buy
Kamagra Oral Jelly	100mg	220 + 18 Sachets	662.24€ 630.70€	Buy

The titration studies, in which most patients received 100 mg, showed similar results.

• Sildenafil strips are an alternative to traditional pill forms.
• The strips dissolve quickly, eliminating need for water to swallow.
• They are convenient for on-the-go use and discreet consumption.
• Possible side effects include headache, flushing, and dizziness.
• Sildenafil strips should be used approximately one hour before activity.
• Not suitable for individuals with certain health conditions; consult a doctor.
• They are typically used in men aged 18 and above.
• The medication works by increasing blood flow to the penis.
• Sildenafil strips can be part of a broader erectile dysfunction treatment plan.
• Side effects may vary depending on individual health status.
• Erectile response may improve with proper use and dosing.
• They are available through licensed pharmacies and online sources.

Figure 7 shows that regardless of the baseline levels of function, subsequent function in

Edit Prescription Anytime

The co-primary efficacy endpoints included both a 4-week assessment of sexual function based on the International Index of Erectile Function (IIEF) questionnaire and an assessment of sexual function after each sexual intercourse based on the Sexual Encounter Profile (SEP) on the daily diary. The six-item, 30-point, erectile function (EF) domain of the IIEF was assessed at baseline, at follow-up visits, and at the end of the study reflecting subjects’ sexual experience during the past 4 weeks. The SEP Question 2 (“Were you able to insert your penis into your partner’s vagina”) and Question 3 (“Did your erection last long enough for you to have successful intercourse?”) were answered immediately after each sexual attempt with binary response (Yes=success, No=failure). Sexual function data were recorded by patients in a daily diary. A total of 475 patients were enrolled and received treatment with SILDENAFIL ORAL FILM, including subjects with comorbidities such as diabetes, dyslipidemia, hypertension and obesity.

Warnings and Precautions

Of these, 354 patients received SILDENAFIL ORAL FILM and 121 patients received placebo without regard to food and alcohol concomitant intake. The initial dose was 50 mg for subjects under 65 years and 25 mg for subjects 65 years or older with dose adjustment permitted up to 50 mg (for subjects 65 years or older), 75 mg or 100 mg or down to 25 mg based on efficacy and tolerability. By the end of the study, 94 (26.6%) and 115 (32.5%) patients in the SILDENAFIL ORAL FILM group were receiving 75 mg or 100 mg respectively. The efficacy of SILDENAFIL ORAL FILM, administered at flexible doses of 25 mg, 50 mg, 75 mg and 100 mg for the treatment of ED, was superior to placebo. Efficacy results are shown in Figure 6. patients treated with sildenafil was better than that seen in patients treated with placebo. At the same time, on-treatment function was better

Rapid Acting

Subgroup analyses by age, race, and ethnicity showed efficacy results consistent with the overall population. *Statistically significant differences vs. placebo; p-value <0.001 IIEF= International Index of Erectile Function, EF = Erectile Function, SEP Q2=Sexual Encounter Profile Question 2, SEP Q3 = Sexual Encounter Profile Question 3, N = Number of Subjects, SD = Standard Deviation, LS = Least Squares, CI = Confidence Interval. Sildenafil was assessed in many clinical studies for its effect on the ability of men with ED to engage in sexual activity and in many cases specifically on the ability to achieve and maintain an erection sufficient for satisfactory sexual activity. Sildenafil was evaluated primarily at doses of 25 mg, 50 mg and 100 mg in 21 randomized, double-blind, placebo-controlled trials of up to 6 months in duration, using a variety of study designs (fixed dose, titration, parallel, crossover). in treated patients who were less impaired at baseline.

• Sildenafil oral strips provide a non-invasive way to treat ED.
• They avoid swallowing pills, which some patients find difficult.
• Strips are often manufactured with pleasant flavors to enhance appeal.
• The medication’s effect can be influenced by food intake.
• Alcohol consumption may reduce effectiveness or increase side effects.
• Sildenafil strips should be used as prescribed and not mixed with other ED drugs.
• These strips are designed for quick absorption in the oral mucosa.
• Overuse or misuse can lead to adverse health effects.
• Proper dosing helps minimize risks of prolonged erections or priapism.
• Sildenafil strips do not cure ED but help manage symptoms.
• They may be used in combination with psychological or lifestyle interventions.
• Always check expiration dates before using sildenafil strips.

Figure7: Effect of Sildenafil and Placebo on Maintenance of Erection by Baseline Score

Condition	Recommended Temperature	Humidity Limit	Shelf Life	Notes
Cool, dry place	15-25°C	<60% RH	2 years	Keep away from sunlight
Avoid moisture exposure	Controlled environment			Humidity-sensitive packaging
Keep in sealed container	N/A			Prevents degradation
Shelf life after opening	1 month			Use within established period

The frequency of patients reporting improvement of erections in response to a global

• Sildenafil oral strips are a fast-acting form of erectile dysfunction medication.
• They are administered orally, dissolving quickly on the tongue for rapid effect.
• Sildenafil strips are often flavored to improve the user experience.
• They contain the same active ingredient as traditional sildenafil tablets.
• These strips are designed for people seeking discreet medication options.
• Onset of action for sildenafil strips can be within 15-30 minutes.
• Proper storage of sildenafil strips involves keeping them in a cool, dry place.
• Dosage strength varies, typically available in 25mg, 50mg, and 100mg.
• Using sildenafil strips without medical consultation is not recommended.
• They may interact with other medications like nitrates or alpha-blockers.
• Sildenafil oral strips are approved for the treatment of erectile dysfunction.
• Users should follow prescribed dosages for safety and effectiveness.

question in four of the sildenafil

For the Media:

A starting oral dose of 25 mg should be considered in those patients [ see Dosage and Administration(2.3)] . Sildenafil metabolism is principally mediated by CYP3A4 (major route) and CYP2C9 (minor route). Therefore, inhibitors of these isoenzymes may reduce sildenafil clearance and inducers of these isoenzymes may increase sildenafil clearance. Cimetidine (800 mg), a nonspecific CYP inhibitor, caused a 56% increase in plasma sildenafil concentrations when co-administered with sildenafil (50 mg) to healthy volunteers. When a single 100 mg dose of sildenafil was administered with erythromycin, a moderate CYP3A4 inhibitor, at steady state (500 mg bid for 5 days), there was a 160% increase in sildenafil Cmax and an 182% increase in sildenafil AUC.

8.7 Hepatic Impairment

In addition, in a study performed in healthy male volunteers, co-administration of the HIV protease inhibitor saquinavir, also a CYP3A4 inhibitor, at steady state (1200 mg tid) with sildenafil (100 mg single dose) resulted in a 140% increase in sildenafil Cmax and a 210% increase in sildenafil AUC. A stronger CYP3A4 inhibitor such as ketoconazole or itraconazole could be expected to have greater effect than that seen with saquinavir. Population pharmacokinetic data from patients in clinical trials also indicated a reduction in sildenafil clearance when it was co-administered with CYP3A4 inhibitors (such as ketoconazole, erythromycin, or cimetidine) [ see Dosage and Administration((2.2) and Drug Interactions (7.4)]. In another study in healthy male volunteers, co-administration with the HIV protease inhibitor ritonavir, which is a highly potent P450 inhibitor, at steady state (500 mg bid) with sildenafil (100 mg single dose) resulted in a 300% (4-fold) increase in sildenafil Cmax and a 1000% (11-fold) increase in sildenafil plasma AUC. At 24 hours the plasma levels of sildenafil were still approximately 200 ng/mL, compared to approximately 5 ng/mL when sildenafil was dosed alone. randomized, double-blind, parallel, placebo-controlled fixed dose studies

17. Patient Counseling Information

Given sildenafil peak plasma concentrations of approximately 1 μM after recommended doses, it is unlikely that sildenafil will alter the clearance of substrates of these isoenzymes. No significant interactions were shown with tolbutamide (250 mg) or warfarin (40 mg), both of which are metabolized by CYP2C9. In a study of healthy male volunteers, sildenafil (100 mg) did not affect the steady state pharmacokinetics of the HIV protease inhibitors, saquinavir and ritonavir, both of which are CYP3A4 substrates. Sildenafil (50 mg) did not potentiate the increase in bleeding time caused by aspirin (150 mg). Sildenafil at steady state, at a dose not approved for sildenafil citrates the treatment of erectile dysfunction (80 mg t.i.d.) resulted in a 50% increase in AUC and a 42% increase in Cmax of bosentan (125 mg b.i.d.).

Can I take S-FILM as often as I want?

Sildenafil was not carcinogenic when administered to rats for 24 months at a dose resulting in total systemic drug exposure (AUCs) for unbound sildenafil and its major metabolite of 20- and 38- times, for male and female rats, respectively, the exposures observed in human males given the Maximum Recommended Human Dose (MRHD) of 100 mg. Sildenafil was not carcinogenic when administered to mice for 18-21 months at dosages up to the Maximum Tolerated Dose (MTD) of 10 mg/kg/day, approximately 0.4 times the MRHD on a mg/m 2basis in a 50 kg subject. There was no impairment of fertility in rats given sildenafil up to 60 mg/kg/day for 36 days to females and 102 days to males, a dose producing an AUC value of more than 25 times the human male AUC. The efficacy of SILDENAFIL ORAL FILM in the treatment of erectile dysfunction was established in part on the basis of efficacy data from trials with the tablet formulation of sildenafil. SILDENAFIL ORAL FILM was evaluated in one randomized, double-blind, placebo-controlled, flexible-dose study (25 mg, 50 mg, 75 mg, 100 mg) over 12 weeks study to evaluate the erectile function of men with erectile dysfunction (ED). (1797 patients) of 12 to 24 weeks duration is shown in Figure 8.

Chemical synthesis

Sildenafil was administered to more than 3,000 patients aged 19 to 87 years, with ED of various etiologies (organic, psychogenic, mixed) with a mean duration of 5 years. sildenafil citrate demonstrated statistically significant improvement compared to placebo in sildenafil 12 5 mg all 21 studies. The studies that established benefit demonstrated improvements in success rates for sexual intercourse compared with placebo. Sildenafil Efficacy Results from Controlled Clinical Studies The effect of sildenafil on one of the major end points, maintenance of erections after penetration, is shown in Figure 7, for the pooled results of 5 sildenafil fixed-dose, dose-response studies of greater than one-month duration, showing response according to baseline function. Results with all doses have been pooled, but scores showed greater improvement at the 50 and 100 mg doses than at the 25 mg dose.

Copyright

Unless otherwise stated, the "Person responsible for the content" holds all text rights. The image rights belong either to the "Person responsible for the content" or to Webbaumeister or their partners.

Availability

The provider of this website and the Web agency Webbaumeister (Basel, Winterthur), their partner for professional web design and search engine optimization, do everything possible to ensure maximum availability of this website.